Randomized Double Blind Phase 3 Study to Assess the Efficacy and Safety of BoNT/A-DP in the Treatment of Glabellar Lines in Comparison With Placebo, Followed by an Open Label Extension Study
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 15 Dec 2017
At a glance
- Drugs Botulinum toxin A (Primary)
- Indications Glabellar lines
- Focus Registrational; Therapeutic Use
- Acronyms BLESSI
- Sponsors Croma Pharma
- 12 Dec 2017 Planned End Date changed from 1 Mar 2018 to 1 Jul 2018.
- 12 Dec 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Jul 2018.
- 01 Feb 2017 Status changed from recruiting to active, no longer recruiting.